Pelthos Therapeutics (NYSEAMERICAN:PTHS) Releases Quarterly Earnings Results

Pelthos Therapeutics (NYSEAMERICAN:PTHS) released its quarterly earnings data on Thursday. The company reported ($6.62) EPS for the quarter, FiscalAI reports. Pelthos Therapeutics had a negative return on equity of 133.40% and a negative net margin of 165.24%.The business had revenue of $15.60 million during the quarter.

Here are the key takeaways from Pelthos Therapeutics’ conference call:

• ZELSUVMI revenue and prescriptions grew strongly: Q2 net product revenue rose 45% sequentially to $15.4 million, while prescribed units increased 48% to 11,925. The company reported more than 25,000 patients prescribed and over 8,000 unique HCP prescribers since launch.
• Market access and commercial execution continue to support demand. Commercial insurance coverage reached 59% and Medicaid coverage 100%, while the 67-territory sales force, PBM contracting, and a recent expert-consensus publication are expected to aid further adoption.
• Pelthos reiterated plans to launch the complementary products XEPI in the first quarter of 2027 and XEGLYZE in the third quarter of 2027. Management expects to leverage its existing sales infrastructure, limiting incremental commercial overhead.
• The company restated its first-quarter 2026 financial statements because of an error in fair-value accounting for related-party convertible debt. Management said the adjustment does not affect cash, revenue, operating expenses, operating loss, or cash flows, but the restatement adds financial-reporting risk.
• Pelthos remains loss-making and faces near-term cost pressure: Q2 net loss was $23.4 million, cash was $24.2 million, and an out-of-specification API issue caused a $0.9 million inventory write-off. Gross-to-net deductions are expected to rise from 29.6% toward the low-to-mid-30% range, or potentially higher if another payer contract is added.

Pelthos Therapeutics Stock Performance

Pelthos Therapeutics stock traded down $1.45 during mid-day trading on Friday, reaching $27.50. 23,287 shares of the stock traded hands, compared to its average volume of 105,434. The stock has a market capitalization of $95.70 million, a PE ratio of -1.26 and a beta of 3.10. The company has a debt-to-equity ratio of 1.41, a current ratio of 2.79 and a quick ratio of 1.86. Pelthos Therapeutics has a 12-month low of $18.19 and a 12-month high of $37.50. The business’s 50-day moving average is $27.49 and its 200-day moving average is $25.14.

Wall Street Analysts Forecast Growth

Separately, Oppenheimer decreased their price objective on shares of Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating for the company in a report on Friday. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Pelthos Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $55.40.

Insider Transactions at Pelthos Therapeutics

In other news, Director Todd C. Davis purchased 35,948 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was acquired at an average cost of $27.82 per share, for a total transaction of $1,000,073.36. Following the purchase, the director directly owned 75,834 shares in the company, valued at $2,109,701.88. This trade represents a 90.13% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 1,638 shares of company stock valued at $43,107 over the last 90 days. Company insiders own 12.70% of the company’s stock.

Hedge Funds Weigh In On Pelthos Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC grew its position in Pelthos Therapeutics by 31.9% during the fourth quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock valued at $422,000 after buying an additional 3,295 shares during the period. Knott David M Jr boosted its stake in shares of Pelthos Therapeutics by 215.5% during the 4th quarter. Knott David M Jr now owns 19,281 shares of the company’s stock worth $598,000 after acquiring an additional 13,169 shares during the last quarter. Persistent Asset Partners Ltd grew its position in shares of Pelthos Therapeutics by 150.0% during the 4th quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock valued at $186,000 after acquiring an additional 3,604 shares during the period. Diadema Partners LP increased its stake in shares of Pelthos Therapeutics by 138.1% in the 4th quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock worth $775,000 after purchasing an additional 14,502 shares in the last quarter. Finally, Cantor Fitzgerald L. P. purchased a new stake in shares of Pelthos Therapeutics in the 4th quarter worth $1,085,000. Hedge funds and other institutional investors own 77.96% of the company’s stock.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).